Jasti Pratima, Kumari Suchitra, Singh Sweta, Anudeep P P
Department of Biochemistry, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
J Family Med Prim Care. 2023 Aug;12(8):1704-1709. doi: 10.4103/jfmpc.jfmpc_320_23. Epub 2023 Aug 29.
Versican is a chondroitin sulphate proteoglycan with raised expression at site of inflammation, and uterine fibroids are associated with local inflammation. Hence, this study aimed to estimate serum Versican levels in pre-menopausal women with uterine fibroids to evaluate its diagnostic efficiency.
This case-control study included forty uterine fibroid cases and 40 healthy controls. Cases clinically evaluated with USG findings, that is number, location of fibroid and volume calculated by prolate ellipse formula a × b × c × 0.523 (a - height, b - width, c - depth). Biochemical investigations, that is serum Versican levels, were estimated by ELISA with total cholesterol, HDLc and LDLc. Triglycerides by fully automated chemistry analysers. Serum biochemical parameters were compared and correlated with volume of fibroid. Area under receiver operating characteristic curve was calculated along with cut-off value to determine diagnostic potential of Versican, differentiating women with fibroids.
In the present study, patients with fibroids had decreased levels of serum Versican (79.43 ± 18.60) as compared to healthy controls (101.81 ± 28.24, < 0.001). There was a statistically significant negative correlation ( = - 0. 307, = 0.04) between serum Versican level and volume of fibroid. Area under ROC was 0.726 (95% CI: 0.616-0.836; = 0.001). The best cut-off value for serum Versican level was 96.90 ng/ml with 90% sensitivity and 48% specificity.
Serum Versican levels were found significantly lower in women with fibroid with a negative correlation with volume of fibroid uterus. Furthermore, extensive study would help in substantiating diagnostic potential of serum Versican in fibroid uterus patients.
多功能蛋白聚糖是一种硫酸软骨素蛋白聚糖，在炎症部位表达升高，而子宫肌瘤与局部炎症有关。因此，本研究旨在评估绝经前子宫肌瘤患者的血清多功能蛋白聚糖水平，以评估其诊断效能。
本病例对照研究纳入了40例子宫肌瘤患者和40例健康对照。病例通过超声检查结果进行临床评估，即肌瘤的数量、位置以及通过椭圆公式a×b×c×0.523（a-高度，b-宽度，c-深度）计算的体积。通过酶联免疫吸附测定法（ELISA）测定生化指标，即血清多功能蛋白聚糖水平，同时检测总胆固醇、高密度脂蛋白胆固醇（HDLc）和低密度脂蛋白胆固醇（LDLc）。甘油三酯通过全自动化学分析仪检测。比较血清生化参数，并将其与肌瘤体积进行相关性分析。计算受试者工作特征曲线下面积（AUC）以及临界值，以确定多功能蛋白聚糖区分子宫肌瘤患者的诊断潜力。
在本研究中，与健康对照（101.81±28.24，P<0.001）相比，子宫肌瘤患者的血清多功能蛋白聚糖水平降低（79.43±18.60）。血清多功能蛋白聚糖水平与肌瘤体积之间存在统计学显著负相关（r=-0.307，P=0.04）。ROC曲线下面积为0.726（95%CI：0.616-0.836；P=0.001）。血清多功能蛋白聚糖水平的最佳临界值为96.90 ng/ml，灵敏度为90%，特异性为48%。
发现子宫肌瘤患者的血清多功能蛋白聚糖水平显著降低，且与子宫肌瘤体积呈负相关。此外，进一步的研究将有助于证实血清多功能蛋白聚糖在子宫肌瘤患者中的诊断潜力。
